Reversing Neuropathy

Regenacy’s HDAC6 inhibitor is a disease-modifying therapy for neuropathies

Regenacy Pharmaceuticals LLC is developing the selective histone deacetylase 6 inhibitor ricolinostat as the first disease-modifying therapy for chemotherapy-induced peripheral neuropathy and diabetic neuropathy.

Regenacy was spun out of Acetylon Pharmaceuticals Inc. during its 2016 acquisition by Celgene Corp. with rights to develop ricolinostat in some non-cancer indications. Celgene has ricolinostat in Phase I/II trials to treat lymphoma and multiple

Read the full 600 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE